Expected new’s10 Apr 2019 08:33
Financial results for year ending 31st December 2018.
Finalisation of riendus loan €6.6m :The Loan will accrue interest at a rate of 1.6%. Repayments commence 3 years after drawdown, and the repayment period thereafter is 10 years.
Commercialisation of Midatech products in China.
Further non-dilutive partnerships to distribute the pipeline of Midatech products.
EU funded clinical consortium programme is evaluating MTX102 for diabetes, and the Company commenced a Phase I clinical study in 2016, with data expected H1 2019.
MTD201 and MTX110 are expected to be the priority focus of the Company this year with phase 1&2 human studies.